D-0301-2019 Class II Terminated

Recalled by Westminster Pharmaceuticals Llc — Olive Branch, MS

FDA drug recall D-0301-2019 was initiated by Westminster Pharmaceuticals Llc on Oct 29, 2018 and is designated Class II. Reason for recall: CGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan. The recall status is terminated (terminated Oct 26, 2021). Affected quantity: 2319 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 19, 2018
Initiation Date
Oct 29, 2018
Termination Date
Oct 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2319 bottles

Product description

Westminster Irbesartan Tablets, USP 150 mg Rx Only Manufactured by: ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788 Manufactured for: Westminster Pharmaceuticals, LLC. Olive Branch, MS 38654 a) 30 count bottle NDC 69367-120-01; b) 90 count bottle NDC 69367-120-03

Reason for recall

CGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.

Distribution pattern

Nationwide.

Code information

Batch Numbers: a) B161005A Exp. 09/30/2019, C161002A Exp. 02/29/2020; b) B161005B Exp. 09/30/2019, C161002B Exp. 02/29/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0301-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0301-2019. Report a data issue: hello@regdatalab.com.